Protein / target
Replicase polyprotein 1ab
Protein at a glance
Biological role
MRNA 5'-cap (guanine-N7-)-methyltransferase
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Multifunctional protein involved in the transcription and replication of viral RNAs.
View complete UniProt function annotationHide complete annotation
Multifunctional protein involved in the transcription and replication of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein
Subcellular location
Domains and Gene Ontology detail (80)Hide
Domains & features
Gene Ontology
- Cdouble membrane vesicle viral factory outer membrane
- Chost cell endoplasmic reticulum membrane
- Chost cell endoplasmic reticulum-Golgi intermediate compartment
- Chost cell endosome
- Chost cell Golgi apparatus
- Chost cell nucleus
- Chost cell perinuclear region of cytoplasm
- F3'-5'-RNA exonuclease activity
- F5'-3' DNA helicase activity
- F5'-3' RNA helicase activity
- FATP binding
- FATP hydrolysis activity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Transcriptional regulation
- ·Multifunctional protein involved in the transcription and replication of viral RNAs. Con…
- ·DNA-templated transcription
- ·symbiont-mediated suppression of host gene expression
- ·Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC)
Proteolysis
- ·cysteine-type endopeptidase activity
- ·ISG15-specific peptidase activity
- ·omega peptidase activity
- ·proteolysis
Metabolic enzyme activity
- ·mRNA 5'-cap (guanine-N7-)-methyltransferase activity
- ·mRNA guanylyltransferase activity
- ·protein guanylyltransferase activity
View underlying pathways (10)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Replicase polyprotein 1ab inhibitor
Indicated for Coronavirus Infections, COVID-19, Severe Acute Respiratory Syndrome, Virus Diseases
Replicase polyprotein 1ab inhibitor
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Indication expanded
Indication expansion: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- Indication expanded
Indication expansion: REMDESIVIR (NDA214787)
- Label change
Label change: REMDESIVIR (NDA214787)
- New publicationEffect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.